US biomarker patent portfolio

RNS Number : 5348K

Proteome Sciences PLC

22 August 2012

 



Proteome Sciences plc

("Proteome Sciences")

PRESS RELEASE

US biomarker patent portfolio

The Directors of Proteome Sciences have been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in light of two recent US court rulings on patent eligibility. We have reviewed the outcomes of the recent U.S. Supreme Court decision on Mayo v. Prometheus and U.S. Court of Appeals for the Federal Circuit decision on Associated Molecular Pathology v. United States Patent and Trademark Office with our US patent attorneys and we conclude that these decisions do not change the status of our issued and pending U.S. applications or impacted our granted U.S. patents which all continue to remain in good standing. The Company continues to fully prosecute and enforce its extensive biomarker patent estate in all territories, including the US to derive maximum value for our shareholders.

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer	Tel: [phone]
Dr. Ian Pike, Chief Operating Officer
Dr. Rainer Voegeli
James Malthouse, Finance Director
Nominated Adviser
Cenkos
Stephen Keys/Camilla Hume	Tel: [phone]
Public Relations
FTI Consulting	IKON Associates
Ben Atwell / Simon Conway / Mo Noonan	Adrian Shaw
Tel:       [phone]	Tel:       [phone]
	Mob :   [phone]

 

END

 

 

MSCGRGDIXXDBGDD